Stock Ratings / Health Care / SLS / options

SRPT (35) GENB (57) ZYME (49) SEPN (63) ⌘ Pro Terminal →

SELLAS Life Sciences Group Inc. (SLS) Options Positioning, Max Pain & Unusual Sweeps

$9.68 -4.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.58

SELLAS Life Sciences Group Inc. (SLS) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $2.05B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SLS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, SELLAS Life Sciences Group Inc. (NASDAQ: SLS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $9.68 (-4.68% 1D, market cap $2.05B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLS ranks #545 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SLS compare to SRPT and GENB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLS carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.8%. By comparison, SRPT (Sarepta Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and GENB (Generate Biomedicines Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $2.02B). Among the 5-stock peer group, SLS leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SLS?

▼

Per SLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001390478), SELLAS Life Sciences Group Inc. generated $0 in revenue, -$26.9M in net income, and -$28.4M in free cash flow against $78.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.58 (-1.03%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SLS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY SLS SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 57% of 52W Range • RSI-14 at 42.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$11.93-12.1% Next Q

Q2 (-2Q)

Grade D$10.49+8.1% Next Q

Q3 (-1Q)

Grade D$11.34-14.6% Next Q

Current

Grade D-$9.68-7.6% Hist 90D α

Trajectory: D (47) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SLS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SLS currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.05) and Max Pain ($10.16) forces dealer call-delta covering toward $16.67.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SLS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SLS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SLS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLS)

✓Walkthrough of SLS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SLS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +92.83%▼ SUPPORT BREAKDOWN

2026-11-02O $10.37H $10.37L $9.68C $9.68VOL 8.36M

RES: $15.39SUP: $9.86SMA50: $12.05SMA200: $8.60

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SLS Butterfly Map → + Track SLS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SLS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SLS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SLS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLS)

Health Care Rank #545 of 1016 ⚔️ SRPT vs SLS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SLS vs. SRPT, GENB, ZYME, SEPN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SELLAS Life Sciences Group Inc. (SLS) ranks #545 by composite RQD confidence (39/100, grade D-) and #257 by equity capitalization ($2.05B). Within this direct 5-issuer industry benchmark cohort, SLS leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with SLS at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SLS ACTIVE SELLAS Life Sciences Group Inc.	D-	39/100	—	—	-21.8%	-4.68%	$2.05B	Benchmark Subject
SRPT Sarepta Therapeutics Inc.	D-	35/100	—	96.0%	-35.0%	-3.17%	$2.03B	/srpt-vs-sls →
GENB Generate Biomedicines Inc.	D+	57/100	—	—	—	-8.31%	$2.02B	/genb-vs-sls →
ZYME Zymeworks Inc.	D	49/100	—	—	-32.2%	-0.35%	$2.02B	/zyme-vs-sls →
SEPN Septerna Inc.	C	63/100	—	—	-20.7%	-2.72%	$2.11B	/sepn-vs-sls →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001390478

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SELLAS Life Sciences Group Inc. (SLS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.9M, operating cash flow of -$28.4M, and free cash flow of -$28.4M (+19.8% YoY). On the balance sheet, SLS closed FY2025 with $78.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$26.9M	-$28.4M	-$28.4M	$78.3M	—
FY2024 (FY)	2024-12-31	$0	-$30.9M	-$35.4M	-$35.4M	$19.4M	—
FY2023 (FY)	2023-12-31	$0	-$37.3M	-$31.4M	-$31.4M	—	—

3. SLS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SLS compare to SRPT and GENB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SLS?

Where is SLS trading relative to its 50-day, 200-day, and 52-week technical levels?

SLS last traded at $9.68 (-4.68% on volume of 6,262,245 shares), positioning the stock -19.67% below its 50-day simple moving average ($12.05) and +12.56% above its 200-day simple moving average ($8.60). Across its 52-week range of $1.39 to $15.88, SLS sits at the 57.2% percentile with a 14-day RSI of 42.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.47 to $10.89).

SLS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SLS's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SLS.

Direct Sub-Reports: SLS RQD Cockpit SLS 12M Forecast SLS Earnings & Move SLS Dividends & DRIP SLS Insiders & 13F SLS Whale Options SLS Profit Sankey SLS News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SLS — SELLAS Life Sciences Group Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:26:51Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SLS scores 39 out of 100, earning a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 7 / 20. Per the RQD rating, this reflects ROIC of -21.8% and an FCF yield of -1.38%. For a prospective investor, negative ROIC and negative FCF yield indicate the business is not currently generating returns on invested capital or free cash flow; any upside case depends on future cash generation that the source data does not yet show.
Whale / 13F Flow: 9 / 20. Per the RQD rating, this pillar covers institutional accumulation and options positioning. The score is modest, suggesting limited evidence of strong institutional conviction in the source data.
Insider Conviction: 3 / 20. Per the RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. It is the weakest pillar, which means the source data offers little insider-side evidence of conviction.
Macro Regime Fit: 10 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market, offering no defensive cushion.
Forensic Balance Sheet: 10 / 20. Per the RQD rating, this reflects an Altman Z of 2.5, a Piotroski F of 2/9, and Debt/Equity of 0.5. The Piotroski score is low, indicating weak financial-quality signals.

Overall, the sharpest valuation tradeoff is that a $2.05B market cap sits against reported losses and negative ROIC, so the stock's price relies on future outcomes not yet visible in the source financials. Upside drivers would need to come from improvements in cash generation; the 52-week range of $1.39 - $15.88 illustrates how wide the price swings have been. This brief is analytical and educational, not personalized financial advice.

Business

SELLAS Life Sciences Group Inc. is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry, per the profile. Revenue is reported as $0.0M across the financial periods provided. Not available in source data for product details, customers, or revenue model.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-28.3M	$-26.9M	N/A	$-28.4M	$71.8M	N/A
FY 2024	$0.0M	$-31.5M	$-30.9M	N/A	$-35.4M	$13.9M	N/A
FY 2023	$0.0M	$-37.9M	$-37.3M	N/A	$-31.4M	N/A	N/A

Per the SEC financials, reported revenue is $0.0M in each period and operating and net losses appear in all three years provided. Gross, operating, and net margins are each 0% per the market data. Per the market data, ROIC is -21.8%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Per the RQD rating, Debt/Equity is 0.5; the source data does not provide a debt figure in the SEC financials, so the balance sheet posture beyond these ratios is not fully resolved.

Recent Catalysts & News Wire Analysis

Per the recent news wire, the items include:

Risk Watch (RED): A Yahoo Finance report on the stock's recent decline and the attention behind it.
Market Wire (YELLOW): A Seeking Alpha piece titled around a REGAL failure risk tied to timing; a Benzinga report on the stock stumbling; a Barchart price-history item; and a Simply Wall St stock analysis.
Catalyst (GREEN): A Stocktwits report on an overnight jump tied to retail interest in a potential buyout and CEO tenure.

The news wire does not provide the underlying detail of these reports beyond headlines and summaries. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

What is the company's revenue model and clinical or commercial pipeline, given revenue of $0.0M across all reported periods?
What drove the reported cash balance of $71.8M in FY 2025 versus $13.9M in FY 2024, and what is the company's runway at the current burn rate?
What is the debt structure behind the Debt/Equity ratio of 0.5, since debt figures are not provided in the SEC financials?
What specific events underlie the RED and YELLOW news items, and does the Congressional or Form 4 insider activity reflect any direction?
What valuation basis (P/E, EV/EBITDA, EPS) applies given that earnings metrics are unavailable?

SLS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SELLAS Life Sciences Group Inc. (SLS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SLS Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 3h ago

SELLAS Life Sciences Group (SLS) Dropped, So What Is Behind The Latest Attention?

Yahoo Finance report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 6h ago

Sellas Life Sciences: The Longer The Wait, The More Likely A REGAL Failure (NASDAQ:SLS)

Seeking Alpha report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 9h ago

SELLAS Life Sciences Stock Stumbles: What's Going On?

Benzinga report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Barchart.com • 12h ago

SLS Price History for Sellas Life Sciences Group Stock

Barchart.com report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stocktwits • 15h ago

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years

Stocktwits report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 18h ago

SELLAS Life Sciences Group (Nasdaq:SLS) - Stock Analysis

Simply Wall St report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 21h ago

We're Not Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn

Moomoo report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago

SELLAS Life Sciences Group, Inc. (SLS) stock price, news, quote and history

Yahoo Finance Singapore report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SLS Bull vs. Bear Conversation Board — What's Your Call at $9.68?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SLS 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $8.93 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SLS (D- • RQD 39/100) a Buy at $10.15?

Welcome to the SLS (SELLAS Life Sciences Group Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.92 (-22.0%)

Spot @ $10.15

Pump the brakes on SLS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SLS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless SELLAS Life Sciences Group Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $12.69 (+25.0%)

Spot @ $10.15

SLS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SLS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.15 (52-wk range $1.39 - $15.88), any beat on forward guidance forces shorts and underweight funds to chase.